NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019. The Company also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $25 million principal amount of notes, solely to cover over-allotments. The offering is expected to close on or about November 3, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
